Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis - European Medical Journal

Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Oncology

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments. At 24 weeks of treatment, 19.1% of patients on the pacritinib arm experienced spleen shrinkage, compared to only 4.7% of patients on the BAT arm.

Presented by Ruben A. Mesa, MD, Mayo Clinic Cancer Center, Scottsdale, AZ, at ASCO 2015.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now